Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Alkermes plc.

NASDAQ: ALKS · Life Sciences · 7 alerts · CIK 1520262

Share price
$46.53Close, Nov 16
Market cap
$7.82B
Shares outstanding
168.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alkermes plc. filings on SEC EDGAR ↗

7:12 AM ET 8-K
Clinical Trial Data

Alkermes Clinical Trial Data

Alkermes announced positive topline results from a Phase 1b proof-of-concept study for ALKS 7290, a novel orexin 2 receptor agonist for the treatment of ADHD. The study demonstrated clinically meaningful improvements in ADHD symptoms as measured by the AISRS and CGI-S scales, marking the first clinical evidence of an orexin agonist's efficacy in ADHD. A Phase 2 study is currently enrolling with data expected in 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.